What Antalgine treats: main uses and benefits

Support for Acute Primary Headaches and Pain Episodes

Antalgine is commonly used to provide symptomatic relief for mild to moderate acute pain, with particular relevance for episodic tension-type headaches and certain episodes of migraine. The formulation is applied for generalized muscular aches, backache, toothache, and period pain (dysmenorrhoea). This application is relevant in contexts involving episodic manifestations of pain.

Support for Fever and Systemic Malaise

The medication is used when groups of symptoms appear suddenly, such as elevated body temperature (fever) alongside generalized physical discomfort. This supportive approach is commonly used to help with the symptoms of colds and influenza, where symptoms may intensify temporarily. This supportive approach is relevant in contexts involving heightened systemic burden, offering symptomatic relief that may help patients cope more steadily with disruptive symptom manifestations.

---

Quick Fact: Relief for Acute Pain

The primary therapeutic use is to provide supportive relief for symptoms associated with acute or episodic changes, helping to ease the intensity of challenging pain and fever manifestations.

Eligibility for Antalgine: Official Regulatory Status

The eligibility profile for Antalgine (Acetaminophen/Caffeine) is defined by official regulatory documents, establishing populations who can, cannot, or must restrict use.

Populations Who Must Not Use (Contraindications)

Antalgine is formally contraindicated and must not be used by patients with a known hypersensitivity to paracetamol, caffeine, or any other ingredient. Use is also strictly prohibited in individuals with severe hepatic impairment (severe liver disease) or severe renal disease (severe kidney disease).

Age and Physiological Restrictions

• Children: Use is not recommended for children under 12 years of age. Adults and adolescents aged 16 years and over are generally eligible.
• Pregnancy and Lactation: Use is not recommended for women who are pregnant or breastfeeding due to the presence of caffeine, as stated in regulatory labeling.

Conditional Use (Caution is Advised)

Regulatory agencies advise that caution is necessary for patients with specific pre-existing conditions. These include individuals with non-cirrhotic alcoholic liver disease, chronic alcoholism, or other conditions associated with glutathione depleted states. Caution is also advised for those with less severe forms of impaired liver or kidney function.

Interactions with other medicines and products

Official regulatory documents define a restrictive interaction profile for Antalgine (Acetaminophen and Caffeine) focused on preventing cumulative toxicity and managing changes in drug exposure.

Interaction Scope

Category	Official Regulatory Statements
Medicinal product categories with documented interactions:	Oral Anticoagulants, Hepatic CYP Inducers (e.g., certain Anticonvulsants), CYP1A2 Inhibitors, Other CNS Stimulants, Bile Acid Sequestrants, Other Acetaminophen-containing medicines.
Specific interacting medicines (if explicitly listed):	Warfarin; Ciprofloxacin; Cimetidine; Phenytoin; Carbamazepine; Isoniazid; Rifampin; Cholestyramine.
Mechanistic basis of interactions (only if stated in label):	Decreased elimination of Caffeine (via CYP1A2 inhibition); Increased metabolism of Acetaminophen into hepatotoxic metabolites (via CYP enzyme induction); Increased anticoagulant effect; Decreased absorption of Acetaminophen.
Timing-based interaction rules (if applicable):	Cholestyramine must be administered with a timing separation of at least one hour after Antalgine to avoid reduced Acetaminophen absorption.
Population-specific interaction notes (if applicable):	Increased risk of hepatotoxicity is documented for patients with underlying liver disease or severe hepatic impairment.

Interaction Classifications (High-Level)

• Contraindicated Combination: Strict prohibition on co-administration with any other Acetaminophen-containing product to prevent dose exceedance and severe liver damage.
• Clinically Significant Interaction: Interaction with Warfarin may increase the anticoagulant effect, requiring monitoring of blood metrics.
• Interaction-Context Constraints: The risk of severe liver damage is officially conditioned on the concurrent, chronic consumption of three or more alcoholic drinks per day.

The regulatory profile consistently highlights risks arising from either additive toxicity or metabolic pathway interference. Official labeling requires careful evaluation of all co-administered products and a defined time separation for absorption-interfering substances.

Central Analgesia via COX-3 Inhibition

Antalgine's core mechanism is mediated by its active metabolites (e.g., 4-MAA), which act as inhibitors of the cyclooxygenase (COX) enzyme system, primarily targeting the centrally expressed COX-3 variant in the brain and spinal cord. This specific inhibition blocks the conversion of arachidonic acid into prostaglandins (PGs) within the Central Nervous System (CNS). The resulting suppression of central PG synthesis directly contributes to the physiological outcomes of reduced pain signal propagation and modulated core body temperature.

---

Dual Modulation of Central Pathways and Muscle Tone

Secondary mechanistic actions include the modulation of descending inhibitory pain pathways, such as those involving the opioidergic and endocannabinoid systems, which enhances their baseline signaling activity. Independently, the drug produces a direct spasmolytic effect, achieved through the relaxation of smooth muscle fibers. This action modifies muscle tone and reduces heightened smooth muscle tension.

Antalgine is a brand name associated with different active ingredients globally, primarily Metamizole or Diclofenac. The parameters for use are established based on the specific active ingredient.

Administration Routes and Dosing

Active Ingredient	Approved Routes	Standard Adult Dosing (Single)	Maximum Daily Dose
Metamizole	Oral, IM, IV, Rectal	500 mg to 1,000 mg	4,000 mg (Oral); 5,000 mg (Parenteral)
Diclofenac	Oral, IM, IV, Rectal, Topical	25 mg to 100 mg (Oral)	150 mg to 200 mg (Oral, varies by form)

Frequency and Special Administration Conditions

The maximum frequency for both active ingredients is typically up to four times daily, requiring an interval of 6 to 8 hours between doses. Use is generally initiated at the lowest effective dose for the shortest duration possible.

Oral Intake:

• Delayed-release or extended-release tablets are typically swallowed whole and are not crushed, split, or chewed.
• Certain oral formulations (e.g., Diclofenac powder packets for migraine) are dissolved in a small, specified amount of water (e.g., 30–60 mL) and consumed immediately on an empty stomach.

Parenteral Administration:

• Intravenous (IV) injection is administered very slowly to minimize risk of reaction.
• Intramuscular (IM) injection is typically administered into a large muscle mass.

Pediatric Dosing (Metamizole): For patients under 15 years, the dose is generally determined weight-based, often in the range of 8–16 mg per kilogram of body weight. If a dose is missed, the standard procedure is to skip the missed dose and continue with the next scheduled dose; a double dose is not taken.

Research evidence / Overview of studies for Antalgine

This overview describes the types of clinical studies that have been conducted for the fixed-dose combination of Acetaminophen and Caffeine, outlining what the research explored and where the limitations lie, according to official scientific sources.

---

Evidence from Clinical Trials for Acute Headache Pain

The primary body of evidence for the Acetaminophen and Caffeine combination involves short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that was studied for acute episodic symptom patterns associated with tension-type headaches and acute migraine attacks. Research primarily focused on outcomes related to physical discomfort. These studies were conducted during periods of increased symptom activity, specifically evaluating participants experiencing these conditions characterized by fluctuating or episodic manifestations.

In these trials, research examined outcomes such as the proportion of participants achieving a pain-free status or experiencing a meaningful reduction in pain intensity at defined time intervals. Research highlights changes measured during the study period in pain-relief measurements compared to a placebo. The evidence for the analgesic adjuvant effect of caffeine, which contributes to understanding symptom patterns, remains a key focus in this research area, and research explored short-term symptom changes associated with the medication.

---

Research on the Combination's Role in Other Acute Pain

The combination was also evaluated in research for conditions associated with acute episodes of pain, such as those studied in post-surgical and dental pain models. These studies typically monitor patient-reported outcomes describing perceived discomfort and the need for rescue pain medication over a short observation period. Research has explored the concept of caffeine acting as an analgesic adjuvant, meaning studies examined how its inclusion was studied for outcomes related to physical discomfort compared to the pain reliever taken alone. The findings describe patterns observed in the studies where the addition of caffeine to analgesics was associated with numerically different scores in pain relief measurements.

---

Study Duration and Research Gaps

The vast majority of the regulatory and peer-reviewed research is derived from single-dose, short-term clinical trials. Because of this focus on acute relief, long-term effects are not fully established, and there is limited information for long-term outcomes or how the medication affects chronic conditions. Furthermore, the evidence base for certain groups remains insufficient, and research does not determine whether an individual in these less-studied populations was observed in similar research settings to the patterns observed in the main adult trials.

Key Studies & References

1. Acetaminophen/Aspirin/Caffeine (StatPearls - General Medical Information & Regulatory Context)

Common questions about Antalgine (FAQ)

---

Q: How long do the effects of Antalgine last?

Regulatory information indicates that the recommended interval between doses is typically 6 to 8 hours. This time frame often corresponds to the duration of the analgesic activity. For the active ingredient Metamizole, the duration of pain-relieving action is specifically reported to be approximately 4–6 hours.

Q: What are the most commonly reported side effects of Antalgine?

While the core safety information focuses on rare, serious risks like blood disorders or liver injury, regulatory documentation also indicates that more commonly reported adverse reactions may include nausea, insomnia, nervousness, and dry mouth, particularly with the Acetaminophen and Caffeine combination.

Q: Does Antalgine cause stomach issues or nausea?

Nausea is a reported adverse reaction. Additionally, if the product contains Diclofenac (an NSAID), official warnings state that there is a documented risk of serious gastrointestinal events, such as ulcers and bleeding, associated with this component.

Q: Can Antalgine be taken with food, or does it need to be on an empty stomach?

Standard tablets can often be administered with or without food. However, the manufacturer may specify that certain specialized forms of the medicine, such as powders, are taken on an empty stomach to support proper absorption.

Q: Which common over-the-counter medicines should not be taken with Antalgine?

Official labeling explicitly warns against taking any other medicine that contains Acetaminophen to avoid exceeding the maximum dose, which carries a risk of severe liver damage. Caution is also advised when combining it with other non-steroidal anti-inflammatory drugs (NSAIDs) if your product contains Diclofenac.

Q: Does Antalgine affect the effectiveness of birth control pills?

Official regulatory documents indicate that the Acetaminophen and Caffeine combination may increase the blood levels of the estrogen component (ethinyl estradiol) found in some oral contraceptives. This interaction should be discussed with a healthcare provider, who can determine if monitoring is needed.

Q: What should I do if the pain doesn't go away after taking Antalgine?

Regulatory guidance advises stopping the use of the medicine and consulting a healthcare provider if symptoms persist, worsen, or change unexpectedly while you are taking it.

Q: Is it safe to drive or operate machinery after taking Antalgine?

Due to the presence of the Central Nervous System (CNS) stimulant (Caffeine) and potential side effects like dizziness or nervousness, patients are advised to exercise caution when driving or operating machinery until they know how the medicine affects them.

Q: Can I take Antalgine if I am already taking an antidepressant?

Caution is advised, as some antidepressants can interfere with how the body processes the active ingredients in Antalgine by affecting liver enzymes. Any such combination warrants discussion with a healthcare provider.

Q: Does Antalgine interact with blood thinners or anticoagulants?

Yes, regulatory documents note a clinically significant interaction with oral anticoagulants, such as Warfarin. Co-administration is considered a clinically significant interaction and requires monitoring of blood metrics by a healthcare professional.

Q: Are there any natural supplements that should be avoided while taking Antalgine?

Official product information advises caution with supplements that can affect liver enzymes, such as St. John's Wort, as they may alter the drug's metabolism and effect. Any herbal supplement use should be discussed with your healthcare provider.

Q: Is Antalgine used for treating fever as well as pain?

Yes, regulatory information classifies this medicine as both an analgesic (pain reliever) and an antipyretic (fever reducer). It is formally indicated for the symptomatic relief of both pain and fever.

Q: Can Antalgine cause changes to sleep patterns?

Yes, the presence of Caffeine, a Central Nervous System (CNS) stimulant, means that adverse reactions such as insomnia (difficulty sleeping) and nervousness are commonly reported in official documentation.

How to Store and Dispose of Antalgine

Antalgine (Acetaminophen/Caffeine tablets) must be stored and handled according to specific conditions documented in the regulatory labeling to maintain its stability.

---

Storage Requirements

Storage Component	Official Requirement
Temperature	Store at controlled room temperature (not above 25 C or 77 F)
Protection	Keep from freezing and protect from moisture and direct light
Container Rule	Store only in the original container and keep the cap closed tightly
Child Safety	Must be kept out of the sight and reach of children

---

Disposal Instructions

Disposal of unused or expired tablets must comply with local regulations. The preferred method is to take the medicine to an authorized drug take-back location. If a take-back program is unavailable, the product should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed into a sealed container before discarding it in the household trash. The tablets are not on the official flush list and should not be discarded down the sink or toilet.